乙肝疫苗市場機會、成長動力、產業趨勢分析及2025-2034年預測

2024 年全球乙肝疫苗市場價值為 67 億美元，預計到 2034 年將以 5.7% 的複合年成長率成長，達到 120 億美元。這一成長軌跡很大程度上受到全球乙肝病例不斷增加的影響，這得益於政府支持的疫苗接種運動和疫苗研發力度的加速。國家免疫計劃和公共衛生意識的提高，使得不同年齡層的人群能夠更廣泛地獲得和接種疫苗。此外，對更有效率、更有針對性的解決方案的需求正在推動疫苗配方和生產的不斷創新。重組技術和遞送機制的進步有助於提高疫苗效力、延長免疫持續時間並減少劑量需求。隨著醫療保健系統致力於減輕肝臟相關疾病的負擔，市場對預防性疫苗接種的需求正在增強，尤其是在高風險族群中。

人們對能夠提供強大而快速免疫反應的新一代疫苗製劑日益成長的偏好，進一步推動了全球範圍內的推廣。這些先進的疫苗經過精心設計，具有增強的抗原穩定性、改進的佐劑系統和最佳化的給藥方式，能夠更快、更持久地預防B型肝炎病毒。與傳統製劑不同，新一代疫苗旨在減少完全免疫所需的劑量，使其更適合大規模免疫接種活動，尤其是在醫療保健資源有限的地區。這項創新對於免疫功能低下者和可能無法有效應答傳統疫苗的高危險群尤為重要。

2024年，聯合疫苗市場規模達45億美元，位居市場首位。預計到2034年，該市場規模將達到78億美元，複合年成長率為5.5%。這些多價疫苗將乙肝疫苗與其他傳染源的免疫接種相結合，減少了所需的注射次數。這種整合方法提高了患者的依從性，並簡化了疫苗接種程序，尤其適用於嬰幼兒。因此，聯合疫苗在兒科醫療保健領域得到了廣泛應用，並得到了公共和私人免疫計劃的支持。由於其高效的接種效率、更廣泛的覆蓋範圍和成本優勢，越來越多的政府和醫療機構選擇這些疫苗，這有助於提高整個社區的疫苗接種率。

預計到2034年，男性市場規模將達到71億美元。這主要是由於男性生理和荷爾蒙水平的差異，這些差異增加了慢性感染和肝臟相關併發症的風險。睪固酮已被證明會影響免疫反應和病毒的持久性，使男性長期感染B型肝炎病毒的風險更高。因此，免疫接種計劃越來越側重於成年男性，成人疫苗製劑的廣泛普及也進一步推動了這一趨勢。意識的增強、醫療保健服務的普及以及對預防保健的推動，將繼續加速該領域的疫苗普及。

2024年，北美乙肝疫苗市場規模達27億美元，預計2034年將達47億美元，複合年成長率為5.4%。憑藉先進的醫療體系和高度的公眾認知度，該地區仍是全球乙肝疫苗領域的主導力量。強大的基礎設施以及政府支持的廣泛疫苗接種計劃，使得兒童和成人的免疫接種率始終保持高位。乙肝的負擔仍然很沉重，尤其是在弱勢群體中，這促使美國和加拿大等國家持續努力，以擴大預防範圍並實現早期免疫覆蓋。

主要市場參與者包括印度血清研究所、VBI疫苗公司、賽諾菲、Biological E、YS Biopharma、葛蘭素史克、深圳康泰生物製品有限公司、巴拉特生物技術公司、Dynavax Technologies、默克公司和吉利德科學公司。為了鞏固市場地位，B型肝炎疫苗領域的公司正專注於產品創新、擴大全球分銷網路並建立策略合作夥伴關係。

領先的企業正在大力投入研發，以開發安全性更高、免疫原性更強的下一代疫苗。許多企業正在利用聯合疫苗平台來擴大覆蓋範圍，並吸引更廣泛的醫療體系。與政府衛生機構、非政府組織和國際組織的合作也使疫苗在新興市場的推廣更加順暢。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 肝病盛行率上升
    • 擴大免疫覆蓋計劃
    • 疫苗配方和生產效率的進步
    • 增加研發投入和活動
  • 產業陷阱與挑戰
    • 嚴格的法規核准流程
    • 疫苗儲存和運輸成本高
  • 市場機會
    • 加強疫苗分發的公私夥伴關係
    • 擴大成人疫苗接種計劃
• 成長潛力分析
• 管道分析
• 監管格局
• 技術進步
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係和合作
  • 擴張計劃

第5章：市場估計與預測：按疫苗類型，2021 - 2034 年

• 主要趨勢
• 單抗原疫苗
• 聯合疫苗

第6章：市場估計與預測：按年齡層，2021 - 2034 年

• 主要趨勢
• 兒科
• 成人

第7章：市場估計與預測：依性別，2021 - 2034 年

• 主要趨勢
• 女性
• 男性

第8章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 醫院
  • 民眾
  • 私人的
• 專科診所
• 其他最終用途

第9章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Bharat Biotech
• Biological E
• Dynavax Technologies
• Gilead Sciences
• GSK
• Merck
• Sanofi
• Serum Institute of India
• Shenzhen Kangtai Biological Products
• VBI vaccines
• YS Biopharma

The Global Hepatitis B Vaccine Market was valued at USD 6.7 billion in 2024 and is estimated to grow at a CAGR of 5.7% to reach USD 12 billion by 2034. The growth trajectory is largely influenced by the increasing number of hepatitis B cases worldwide, backed by government-backed vaccination campaigns and accelerated vaccine development efforts. National immunization programs and expanded public health awareness have led to greater access and uptake of vaccines across various age groups. Additionally, demand for more efficient and targeted solutions is pushing continuous innovation in vaccine formulation and manufacturing. Advances in recombinant technology and delivery mechanisms are contributing to higher efficacy, longer-lasting immunity, and reduced dosage requirements. As healthcare systems aim to reduce the burden of liver-related diseases, the market is witnessing stronger momentum for preventive vaccination, particularly among at-risk populations.

The rising preference for next-generation formulations that deliver robust and rapid immune responses further supports adoption globally. These advanced vaccines are being engineered with enhanced antigen stability, improved adjuvant systems, and optimized delivery methods to generate quicker and more sustained protection against hepatitis B. Unlike traditional formulations, next-gen vaccines aim to reduce the number of doses required for full immunity, making them more suitable for large-scale immunization campaigns, especially in regions with limited healthcare access. This innovation is particularly crucial for immunocompromised individuals and high-risk groups who may not respond effectively to conventional vaccines.

In 2024, the combination vaccines segment led the market with a value of USD 4.5 billion and is forecasted to reach USD 7.8 billion by 2034, growing at a CAGR of 5.5%. These multivalent vaccines combine hepatitis B protection with immunization against other infectious agents, reducing the number of injections required. This integrated approach improves patient compliance and simplifies vaccine schedules, especially for infants and children. As a result, combination vaccines have gained widespread adoption in pediatric healthcare, supported by both public and private immunization programs. Governments and providers increasingly opt for these vaccines due to their efficiency in administration, broader coverage, and cost advantages, helping raise vaccination rates across communities.

The male segment is expected to reach USD 7.1 billion by 2034. This is largely driven by biological and hormonal differences that increase the risk of chronic infection and liver-related complications in men. Testosterone has been shown to influence immune response and virus persistence, placing males at a greater risk of prolonged hepatitis B infection. As a result, immunization programs have increasingly focused on adult men, with widespread availability of adult vaccine formulations supporting this trend. Growing awareness, better access to healthcare, and a push for preventive care continue to accelerate vaccine adoption in this segment.

North America Hepatitis B Vaccine Market was valued at USD 2.7 billion in 2024 and is projected to reach USD 4.7 billion by 2034 at a CAGR of 5.4% through 2034. The region remains a dominant force in the global hepatitis B vaccine landscape due to its advanced healthcare delivery systems and high public awareness. Strong infrastructure, along with extensive government-backed vaccination programs, has enabled both pediatric and adult immunization rates to remain consistently high. The burden of hepatitis B remains significant, especially in vulnerable populations, prompting sustained efforts toward widespread prevention and early immunization coverage in countries like the U.S. and Canada.

Key market players include Serum Institute of India, VBI Vaccines, Sanofi, Biological E, YS Biopharma, GSK, Shenzhen Kangtai Biological Products, Bharat Biotech, Dynavax Technologies, Merck, and Gilead Sciences. To strengthen their market position, companies in the hepatitis B vaccine segment are focusing on product innovation, expanding their global distribution networks, and engaging in strategic partnerships.

Leading players are investing heavily in R&D to develop next-generation vaccines with improved safety profiles and stronger immunogenicity. Many are leveraging combination vaccine platforms to increase coverage and appeal to broader healthcare systems. Collaborations with government health agencies, NGOs, and international organizations are also enabling smoother vaccine rollouts in emerging markets.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Vaccine type
  • 2.2.3 Age group
  • 2.2.4 Gender
  • 2.2.5 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of liver diseases
    • 3.2.1.2 Growing immunization coverage programs
    • 3.2.1.3 Advancements in vaccine formulation and production efficiency
    • 3.2.1.4 Increasing R&D investment and activities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory approval processes
    • 3.2.2.2 High cost of storage and transportation of vaccine
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing public-private partnerships for vaccine distribution
    • 3.2.3.2 Expanding adult vaccination programs
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Technological advancements
• 3.7 Future market trends
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Single antigen vaccine
• 5.3 Combination vaccine

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Pediatric
• 6.3 Adult

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Female
• 7.3 Male

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
  • 8.2.1 Public
  • 8.2.2 Private
• 8.3 Specialty clinics
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Bharat Biotech
• 10.2 Biological E
• 10.3 Dynavax Technologies
• 10.4 Gilead Sciences
• 10.5 GSK
• 10.6 Merck
• 10.7 Sanofi
• 10.8 Serum Institute of India
• 10.9 Shenzhen Kangtai Biological Products
• 10.10 VBI vaccines
• 10.11 YS Biopharma